Explore this article's sources with AI
Follow PeptideMethods on Google
What semaglutide actually costs in the UK
NHS patients may pay £9.90 per item in England, while NICE lists Wegovy packs at £73.25 to £175.80 before a confidential NHS discount.
Why we wrote this. Official list prices, NHS patient charges and private quotes are different figures, and seller vials are not authorised packs.
In this article (7 sections)
There is no single UK price for semaglutide. For an NHS prescription in England, the current patient charge is £9.90 per item unless an exemption applies. A prescription prepayment certificate costs £32.05 for three months or £114.50 for twelve months[1]. In Scotland, Wales and Northern Ireland, ordinary NHS prescriptions are free. Private treatment is different: the patient pays the pharmacy or clinic's price, which can include the medicine, prescribing and service fees.
The official Wegovy list prices recorded by NICE are £73.25 per pack for the 0.25 mg, 0.5 mg and 1 mg pens, £124.53 for 1.7 mg and £175.80 for 2.4 mg, excluding VAT. Each pack contains one pen that delivers four doses. NICE also records a confidential NHS commercial discount[2]. Those figures are list prices, not a promise of what a private patient pays and not the cost of every semaglutide product.
Three different prices are often confused
The first number is the NHS patient charge. It is a flat charge per prescription item in England and does not rise with the medicine's list price. A person who qualifies for an exemption pays nothing. The second number is the published list price used in health-technology assessment and reimbursement discussions. The third is the private cash price charged by a particular provider. These numbers answer different questions.
The £9.90 charge therefore does not mean the NHS buys semaglutide for £9.90. NICE says the NHS has a commercial arrangement that makes Wegovy available at a discount from the published list price, but the size of that discount is confidential[2]. The public list price is still useful for understanding the pack, but it is not the NHS net acquisition cost.
A private quote is not an official UK tariff. Providers set their own prices and may bundle clinical review, dispensing or follow-up. A headline first-month offer can use the lowest-strength pack and say little about later costs. PeptideMethods does not use research-vendor listings as evidence of a UK medicine price.
Wegovy, Ozempic and Rybelsus are not one pack
Semaglutide is the active ingredient in distinct authorised products. Wegovy is the product assessed by NICE for managing overweight and obesity. Ozempic is an injectable semaglutide product for type 2 diabetes, and Rybelsus is an oral tablet product. Their presentations, indications and pack prices are separate. A price quoted for Wegovy should not be relabelled as the price of Ozempic, Rybelsus or a generic seller vial. See the semaglutide overview for the product identities.
The difference is not cosmetic. A UK marketing authorisation covers a defined finished product, strength and presentation. A vial sold online as semaglutide is not Wegovy, Ozempic or Rybelsus. It has no official branded-pack list price merely because it claims the same active ingredient.
This also separates semaglutide from tirzepatide, sold in the authorised Mounjaro product, and from retatrutide, which is not authorised in the UK. Prices cannot be transferred between molecules or between authorised packs and seller products.
What NHS access changes
NICE recommends semaglutide for weight management only within specified conditions. The recommendation includes at least one weight-related comorbidity, BMI thresholds, use within a specialist weight-management service and a maximum treatment period of two years[3]. The exact criteria and local service capacity determine whether a patient can receive Wegovy through the NHS. A marketing authorisation alone does not guarantee NHS access.
Where the NHS prescribes the medicine, the patient usually faces the ordinary prescription-charging rules rather than the private retail price. Where the NHS criteria or local service route are not met, that does not make a private prescription automatic. A private prescriber still has to decide whether treatment is appropriate and issue a valid prescription.
For readers comparing access, the UK regulation hub explains how prescription-only status and authorised supply fit together. The price question begins only after product identity, indication and lawful prescribing have been established.
What a private patient can say with confidence
A private patient should expect the price to vary by product, strength and provider. The published Wegovy list price gives a reference point for the medicine pack. It does not include every service fee, does not reveal the confidential NHS price and does not bind a private pharmacy to a uniform retail charge.
Before agreeing to treatment, ask for the full recurring price rather than only the starter offer. The useful questions are whether the quote includes the medicine, prescribing review, delivery and follow-up, and how the price changes across strengths. That is cost clarification, not dosing advice. Strength and treatment decisions belong with the prescriber.
Do not compare a regulated pharmacy quote with a seller vial as though they were two prices for the same pack. The low seller number may exclude a valid prescription, regulated dispensing, verified product identity and storage controls. It may also represent a product that is illegal to supply. A cheaper label is not evidence of a comparable medicine.
The current official figures
As checked on 8 November 2026, the NHS England prescription charge shown on GOV.UK is £9.90 per item. The three-month prepayment certificate is £32.05 and the twelve-month certificate is £114.50[1]. These are patient charges across NHS prescriptions, not semaglutide-specific prices.
NICE's Wegovy appraisal lists £73.25 for the 0.25 mg, 0.5 mg and 1 mg packs, £124.53 for 1.7 mg and £175.80 for 2.4 mg, excluding VAT. One pack contains a pen delivering four doses[2]. The confidential NHS discount means these public figures should not be described as what the health service actually pays.
Zero official price should never be inferred from an absent pack. Likewise, a seller's vial price is not an official UK semaglutide price. Official pricing follows a defined authorised product. Where the product is unclear, a precise comparison is not possible.
Why very cheap offers are a safety signal
The MHRA warns people to avoid weight-loss medicines from unregulated websites and social media. It says authorised GLP-1 medicines should be prescribed by a healthcare professional and that fake products can contain the wrong substance or harmful contaminants[4]. A price far below regulated pharmacy quotes should be treated as a reason to verify the seller and product, not as proof of a bargain.
The agency provides a GOV.UK service for reporting suspicious online sellers[5]. If a product causes a suspected side effect or appears defective, the Yellow Card scheme accepts reports from patients and the public[6]. Seek medical help promptly if you become unwell.
What we cannot publish as a national price
There is no single official UK private cash price covering every provider, product and service package. A snapshot of clinic websites would be a market comparison, not a national medicine tariff, and it would age quickly. This page therefore reports the official patient charge and NICE list-price record, then explains what each figure excludes.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Regulatory disclaimer: This page reflects our understanding of UK pricing and access as of 8 November 2026. Prices, charges and eligibility rules change. Verify the current position with the NHS, NICE and your dispensing pharmacy. PeptideMethods.com does not provide legal advice.
Frequently asked
How much does semaglutide cost on the NHS in England?
A patient who pays NHS prescription charges currently pays £9.90 per item, regardless of the medicine's list price. Exempt patients pay nothing. NHS access to Wegovy still depends on NICE criteria and local service capacity.
What is the official Wegovy list price in the UK?
NICE records £73.25 for 0.25 mg, 0.5 mg and 1 mg packs, £124.53 for 1.7 mg and £175.80 for 2.4 mg, excluding VAT. Each pack has one pen delivering four doses.
Does the NHS pay the published Wegovy list price?
Not necessarily. NICE states that a commercial arrangement gives the NHS a discount, but the size is confidential. The public list price is not the NHS net acquisition cost.
Is there one official private semaglutide price?
No. Private providers set prices by product, strength and service package. Quotes may include prescribing, dispensing, delivery or follow-up. A private quote is not a national tariff.
Is a cheap semaglutide vial comparable with Wegovy?
No. Wegovy is a defined authorised finished product. A seller vial does not inherit its authorisation, pack identity, quality controls or official list price because the label claims semaglutide.
Sources
- [1]GOV.UK: NHS prescription charge and prescription prepayment certificate pricesTier 1 · primary↩
- [2]NICE TA875: information about semaglutide, Wegovy list prices and NHS commercial arrangementTier 1 · primary↩
- [3]NICE TA875: recommendations for semaglutide in weight managementTier 1 · primary↩
- [4]MHRA: No summer shortcut for safe weight loss (24 July 2026)Tier 1 · primary↩
- [5]MHRA: report a suspicious online seller of medicinesTier 1 · primary↩
- [6]MHRA: Yellow Card scheme guidanceTier 1 · primary↩
No revisions yet. First published .